Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423))

Short Communication Volume 4 Issue 6

Favipiravir and Coronavirus

Marcos Aurelio Gomes Da Silva*

Federal University of Juiz De Fora, Brazil

*Corresponding Author: Marcos Aurelio Gomes Da Silva, Federal University of Juiz De Fora, Brazil.

Received: March 24, 2020; Published: May 07, 2020

×

 Favipiravir is an antiviral drug that selectively inhibits the RNAdependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl- 5'-triphosphate (RTP). Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options. Recently, T-705 has been shown to give 100% protection against aerosol Ebola virus E718 infection in immune-deficient mice as well as inhibiting Ebola virus infection in cell culture.

×

References

×

Citation

Citation: Marcos Aurelio Gomes Da Silva. “Favipiravir and Coronavirus” Acta Scientific Pharmaceutical Sciences 4.6 (2020): 02.



Member In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 15, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US